Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Spiraeoside is a naturally occurring flavonoid glycoside, specifically the 4'-O-glucoside of quercetin. It is a primary bioactive component of meadowsweet (*Filipendula ulmaria*) and is also found in other botanical sources such as onions. Spiraeoside exhibits antioxidant, anti-inflammatory, and geroprotective properties. Research has focused on its ability to modulate neuroinflammation and proteostasis, suggesting potential therapeutic applications in aging-related neurodegenerative disorders like Parkinson's disease. It is typically encountered as a constituent of herbal extracts or dietary supplements rather than as a purified pharmaceutical agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on spiraeoside.